ABSTRACT
H
epatitis C virus (HCV) infection is associated with chronic liver disease, including hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma (1) . Recent licensing of directly acting antivirals (DAAs) has considerably improved therapeutic options, and novel drug combinations reach cure rates of more than 90% (2). However, natural or treatment-induced virus elimination does not prevent reinfection by HCV. Moreover, many of ca. 160 million infected individuals are not diagnosed, and the vast majority of HCV patients have not been treated (3) . Therefore, development of a prophylactic vaccine that efficiently prevents virus transmission is a major challenge for global control of hepatitis C. However, advances in HCV vaccine research are hampered by a lack HCV-permissive, immunocompetent animal models.
HCV, a plus-strand RNA virus and member of the family Flaviviridae, has a narrow species tropism. Besides humans, only chimpanzees are naturally susceptible to chronic HCV infection. However, high costs and ethical concerns severely limit utilization of chimpanzees for research purposes. Thus, understanding of the mechanisms that limit HCV replication in other animals, for instance, mice, is an important step to ultimately develop a robust animal model for HCV. Encouragingly, recent advances have highlighted key prerequisites for HCV infection of murine liver cells. First, occludin and CD81 have been recognized to determine HCV species tropism at the level of viral cell entry (4) . Importantly, this blockade can be overcome by engineering mice to express human occludin and CD81 (5) or by adaptation of HCV to usage of mouse CD81 (6) . Second, HCV replication in murine embryonic fibroblasts (7, 8) , in mouse liver-derived cells (9) , and in mouse livers in vivo (10) is heavily impaired by innate immune signaling, since inactivation of host molecules involved in viral RNA sensing, innate immune signaling, or responsiveness to interferons substantially increases HCV replication. Therefore, ablation of distinct innate immune signaling molecules combined with overexpression of essential human entry factors has emerged as a valid strategy to allow HCV propagation in mouse cells in vitro and in vivo (9, 10) . However, this environment is only partially immunocompetent, thus limiting utility for immunological studies. Moreover, the efficiency of HCV propagation remains modest either because additional immune control mechanisms curtail HCV replication or because essential human replication cofactors are lacking.
In human cells, the HCV protease NS3-4A interferes with innate immune signaling by cleaving TRIF (TIR domain-containing adaptor-inducing beta interferon [IFN-␤]) (11) and MAVS (mitochondrial antiviral signaling protein; also known as IPS-1, VISA, or Cardif) (12) , two critical adaptor proteins that link cellular pattern recognition receptors with production of interferons. Nevertheless, viral interference in human cells is not complete, as HCV infection of human liver cells triggers production of both type I and III interferons which partially control HCV replication (13) (14) (15) (16) . Moreover, distinct human IFN-induced effector proteins relevant for control of HCV replication have been identified (17) (18) (19) . In contrast, little is known about murine IFN-induced antiviral programs that limit HCV replication. Moreover, the interferon-stimulated genes (ISGs) that establish antiviral defenses against HCV replication in mouse cells are unknown. Finally, the level of interference of HCV with murine innate immune signaling cascades is incompletely defined. Given the importance of innate immunity for control of HCV replication in both the human and murine systems, in this study, we wished to better define the relevance of innate immune control and HCV interference for propagation of HCV in mouse liver cells.
MATERIALS AND METHODS
Reagents. Mouse IFN-␣ and IFN-3 were purchased from eBioscience and R&D Systems, respectively. Boceprevir and 2=C-methyladenosine (2=CMA) were gifts from Marc Windisch (Institute Pasteur Korea, Seongnam, South Korea) and Tim Tellinghuisen (The Scripps Research Institute, FL), respectively. High-molecular-weight (HMW) poly(I·C) was purchased from InvivoGen. HCV subgenomic replicon (HCV-SGR) RNA was generated in-house by in vitro transcription as described previously (9) .
Cell culture and generation of cell lines. All cells were cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen) supplemented with 2 mM L-glutamine, nonessential amino acids, 100 U/ml of penicillin, 100 g/ml of streptomycin, and 10% fetal calf serum (FCS) at 37°C and 5% CO 2 . MLT-MAVS Ϫ/Ϫ and MLT-IFNAR Ϫ/Ϫ cells were generated in a previous study (9) . Stable cell lines expressing miR122 were created by lentiviral gene transfer as described earlier (9) . MLT-MAVS Ϫ/Ϫ miR122 cells with stable restoration of human MAVS (hMAVS) or mouse MAVS (mMAVS) were created through lentiviral gene transduction followed by passaging in the presence of antibiotic pressure (5 g/ml of blasticidin) as described previously (9) .
The generation of HEK 293T-MAVS Ϫ/Ϫ cells was done by targeting the critical exons of the MAVS gene in 293T cells using the following transcription activator-like effector nuclease (TALEN) target site: 5=-TT GCTGAAGACAAGACCTAT/AAGTATATCTGCCGC/AATTTCAGCA ATTTTTGCAA-3=. TALEN plasmids were assembled as described in reference 3. HEK 293T cells were plated at a density of 2 ϫ 10 4 cells per well of a 96-well plate. The next day, TALEN plasmids were transfected using GeneJuice transfection reagent (Merck Millipore) at a ratio of 1:1 (100 ng of each plasmid). Subsequently, all-allelic knockout clones were isolated. In short, 14 days after limiting dilution cloning, growing monoclones were selected by bright-field microscopy. Identified clones were trypsinized and expanded in two separate wells. One well was used to recover genomic DNA, and subsequently, the target region of interest was amplified in a two-step PCR and subjected to deep sequencing. Knockout cell clones were identified as cell clones harboring all-allelic frameshift mutations using the OutKnocker webtool at http://www.outknocker.org /. To further confirm the knockout, Western blotting was performed. Note that the faint band visible in Western blotting (see Fig. 2E ) is a result of a nonspecific cross-reaction of the antibody used. This was confirmed by further Western blotting and genotyping, which verified proper knockout of MAVS (data not shown). Genotypes of the respective knockout cell lines are available upon request.
Mice. Normal C57BL/J6 and BALB/c mice were purchased from Charles River Labs. C57BL/6 mice lacking functional receptors for type I and III IFN (20) were bred at University Medical Center Freiburg. Mouse experiments were carried out using animals between 6 and 12 weeks of age. Mice were housed under specific-pathogen-free conditions at the Twincore animal facility, and all experiments were conducted according to institutional guidelines for animal care and use and in compliance with regulations of German animal welfare law.
In vivo immortalization and generation of tumor cell lines. Intrahepatic tumors were induced in IFNAR Ϫ/Ϫ IFNLR1 Ϫ/Ϫ double-knockout mice (20) by retrograde liver transduction with oncogenic transposon plasmids using hydrodynamic injection. For this purpose, mice received 30 g of total plasmid DNA (8 g of pT/KRas-G12V, 8 g of pT3/EF1␣-myrAkt1, 8 g of pT3/EF1␣-shRp53, and 6 g of pPGK-SB13). A more detailed description of the used plasmids and plasmid construction can be found elsewhere (9) . The pPGK-SB13 plasmid for expression of Sleeping Beauty SB13 was kindly provided by David A. Largaespada (University of Minnesota). For tumor induction, oncogenic transposon plasmids were injected into mice in 0.9% saline at a final volume of 10% of the animal's body weight via tail vein injection within 5 s. Once tumors became palpable (5 to 12 weeks postinjection), mice were sacrificed and tumors were harvested for subsequent isolation of immortalized cell lines. Isolated tumors were dissected and incubated for 30 min at 37°C in RPMI 1640 plus GlutaMAX supplemented with 200 g/ml of collagenase IA, collagenase IV, and hyaluronidase IV, 300 g/ml of dispase, and 50 g/ml of DNase I (Sigma-Aldrich). Separated cells were purified using a 40-m strainer, washed once, and then cultivated in DMEM plus GlutaMAX with 10% FCS and penicillin-streptomycin at 37°C in 5% CO 2 . Cells were then cultivated as described previously (9) . Deletions of IFNAR and IFNLR1 genes were confirmed by quantitative reverse transcription-PCR (qRT-PCR).
PMH isolation. Primary mouse hepatocytes (PMHs) were isolated from BALB/cJ and/or C57BL/6J mice by a modified 2-step Liberase perfusion (21, 22) . Briefly, mice were anesthetized using ketamine (Albrecht) and Rompun (Bayer). The body cavity was opened and a catheter was placed into the portal vein and connected to a flow pump, which pumped media prewarmed at 37°C from a water bath into the catheter. The liver was first perfused with Earle's balanced salt solution (EBSS) (GIBCO) solution containing 0.5 mM EGTA (Sigma-Aldrich) and 10 mM HEPES buffer (Sigma). Subsequently, EBSS supplemented with 10 mM HEPES buffer and Liberase (Roche) at 100 g/liter was applied for enzymatic digestion of the tissue at 37°C. After digestion for 10 to 12 min, the liver was carefully disconnected and tissue was manually disrupted with a sterile scissors and scalpel in DMEM (GIBCO Germany) containing 10% FCS. The suspended hepatocytes were passed through a 100-m nylon filter into 50-ml Falcon tubes. The cell suspensions were centrifuged twice at 300 rpm for 5 min at 4°C, and the cell pellet was resuspended in ice-cold DMEM containing 10% FCS (PAN Biotech). Cell viability was tested by trypan blue (Fluka).
Transient HCV luciferase replication assay. Methods for transfection of HCV-SGR RNA are described elsewhere (9) . Luciferase activity of replicating HCV-SGR was analyzed as described elsewhere (9, 23) .
Lentiviral pseudoparticle production. Lentiviral, HIV-based pseudotypes were created essentially as described previously (9) . Briefly, HEK 293T cells were transfected with envelope glycoprotein expression construct pcz-VSV-G, lentiviral gag-pol expression construct pCMV⌬R.74, and lentiviral genomic backbone for the desired gene expression using a polyethyleneimine (PEI) method (Carl Roth).
Plasmids. The lentiviral plasmid pWPI-JFH1-NS3-4A-BLR encodes the NS3-4A protease of HCV strain JFH1. The lentiviral plasmids pWPIhMAVS-BLR, pWPI-mMAVS-BLR, pWPI-HA-hMAVS-GUN, and pWPI-HA-mMAVS-GUN encode human or mouse MAVS variants with or without a hemagglutinin (HA) tag. Lentiviral plasmid pWPImIFNLR1-BLR encodes the mouse ortholog of a high-affinity type III IFN receptor (NM174851.3). All pWPI constructs were cloned in-house with detailed cloning strategies that are available upon request. The plasmid pTRIP-pre-miR-122-puro was described previously and given as a kind gift from Matthew Evans (Mount Sinai School of Medicine, NY) (24) . The IFN-␤ promoter reporter plasmid (pGL3b-IFN-␤ promoter-Luc) was kindly provided by Stefan Lienenklaus (HZI, Braunschweig, Germany).
Western blotting. Cells were washed with phosphate-buffered saline (PBS) and lysed in RIPA buffer (0.3 M NaCl, 20 mM Tris-HCl [pH 8], 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS] , and 1% Triton X-100) for 30 min on ice. Total protein content was determined by the Bradford assay. Equal protein amounts for each sample were mixed with 2ϫ denaturing protein sample buffer (200 mM Tris-HCl [pH 8.8], 5 mM EDTA, 0.1% bromophenol blue, 10% sucrose, 3.3% SDS, 2% 2-mercaptoethanol [2-ME]), heated for 5 min at 98°C, loaded onto an 11% SDS gel, and resolved by electrophoresis. Subsequently, proteins were transferred to a polyvinylidene difluoride membrane which was then blocked with 5% milk in PBS containing 0.5% Tween (PBS-T) for 1 h at room temperature. The membrane was then incubated with either anti-NS3337 tag (1:300), anti-HA tag (1:1,000; Covance), anti-FLAG tag (1:1,000; SigmaAldrich), anti-hMAVS or anti-mMAVS (both at 1:300; Santa Cruz), antigreen fluorescent protein (anti-GFP, 1:1,000; Santa Cruz), or anti-␤-actin (1:1,000; Sigma-Aldrich), followed by incubation with secondary antibody coupled to horseradish peroxidase (Sigma-Aldrich). Bound antibodies were detected with the ECL Plus detection system (GE Healthcare).
Quantitative reverse transcription-PCR. Total RNA was extracted using the Nucleospin RNA II kit (Macherey-Nagel) by following the manufacturer's protocol. Subsequently, 2 l was reverse transcribed into cDNA using the PrimeScript First Strand cDNA synthesis kit (TaKaRa), and PCR was carried out using a 400 nM concentration of primers together with SYBR Premix Ex Taq (TaKaRa) and was quantified with a LightCycler480 (Roche). Murine glyceraldehyde-3-phosphate dehydrogenase (mGAPDH) mRNA levels were always quantified in parallel. Primers used this study are as follows: for mouse IFN-␤, CTGCGTTCCTGCT GTGCTTCTCCA (sense) and TTCTCCGTCATCTCCATAGGGATC (antisense) (25) ; for mouse IFN-2/3, AGCTGCAGGCCTTCAAAAAG (sense) and TGGGAGTGAATGTGGCTCAG (antisense) (26) ; for mouse GAPDH, TTCACCACCATGGAGAAGGC (sense) and GGCATCGACT GTGGTCATGA (antisense) (25) ; for mouse viperin, AACCCCCGTGAG TGTCAACTA (sense) and AACCAGCCTGTTTGAGCAGAA (antisense) (27) ; for mouse ISG15, AGCAATGGCCTGGGACCTAAA (sense) and AGCCGGCACACCAATCTT (antisense) (28); and for mouse IFIT1, CA GAAGCACACATTGAAGAA (sense) and TGTAAGTAGCCAGAGGA AG (antisense) (29) .
Immunofluorescence. HCV replication was visualized by indirect immunofluorescence as described previously (23) . HCV antigen-expressing cells were detected using the mouse monoclonal NS5A-9E10 antibody (kindly provided by Charles M. Rice, Center for the Study of Hepatitis C, The Rockefeller University, NY) at a dilution of 1:1,000. Bound primary antibodies were detected using goat anti-mouse IgG-specific secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 546 (SigmaAldrich) at a dilution of 1:1,000. Nuclear DNA was stained using 4=,6-diamidino-2-phenylindole (DAPI) at a dilution of 1:3,000.
Statistical methods. GraphPad Prism 6 software was used for data analysis using a one-way analysis of variance (ANOVA) adjusted with Bonferroni's multiple-comparison test. P values of Ͻ0.05 (single asterisks in figures) were considered statistically significant, whereas P values of Ͻ0.01 (double asterisks) and Ͻ0.001 (triple asterisks) were considered highly significant.
RESULTS
mMAVS restricts HCV replication in MLT cells. Previously, we have reported that HCV replicons and full-length RNAs efficiently propagate in transfected mouse liver-derived tumor (MLT) cells which lack endogenous expression of MAVS (MLT-MAVS Ϫ/Ϫ miR122 cells) (9) . These cells therefore provide a unique environment to test the importance of mouse MAVS (mMAVS) for restricting HCV replication and to explore the ability of HCV to interfere with mMAVS function.
To this end, we confirmed the absence of endogenous mMAVS expression in these cells and subsequently restored mMAVS expression by lentiviral gene transfer. Murine Hep56.1D cells and human Huh-7.5 cells served as controls for specific detection of mMAVS in our protein expression analysis (Fig. 1A) . Parental MLT-MAVS Ϫ/Ϫ miR122 cells were not responsive to transfection of poly(I·C), a mimic of double-stranded RNA which triggers RIG-I-like receptor (RLR [30] )-dependent signaling via MAVS to produce of IFN-␤ mRNA (Fig. 1B) . In contrast, restoration of mMAVS expression in these cells (Fig. 1A) resulted in upregulation of IFN-␤ mRNA upon transfection of poly(I·C) to a level similar to the one observed in poly(I·C)-transfected Hep56.1D cells (Fig. 1B) . Thus, we concluded that repair of mMAVS expression in MLT-MAVS Ϫ/Ϫ miR122 cells restored the sensitivity of these cells to RLR-dependent recognition of viral double-stranded RNA comparable to that of cells expressing endogenous levels of mMAVS (e.g., Hep56.1D). Next, we analyzed the influence of reintroducing mMAVS on permissiveness for HCV replication. To this end, cells were transfected with a subgenomic JFH1 replicon expressing luciferase or a control luciferase replicon with an inactivating mutation in the viral NS5B polymerase. HCV replication in transfected cells was monitored by luciferase assays (Fig. 1C ) and indirect immunofluorescence (Fig. 1D) . As reported previously (9), parental MLT-MAVS Ϫ/Ϫ miR122 cells sustained vigorous HCV RNA replication, as evidenced by rapid accumulation of luciferase activity (Fig. 1C) and by detection of numerous NS5A-expressing cells (Fig. 1D) . In contrast, reintroduction of mMAVS ablated HCV replication to background levels, with luciferase activity indistinguishable from that of cells transfected with the replication-incompetent viral RNA (Fig. 1C) and with no NS5A-positive cells detectable (Fig. 1D) . Therefore, repair of mMAVS expression in MLT-MAVS Ϫ/Ϫ miR122 cells efficiently restored innate immune signaling and restricted HCV RNA replication.
HCV interferes with mouse and human MAVS to similar levels. The above-described findings suggested that HCV replication is efficiently restricted by mMAVS potentially because the HCV NS3-4A protease fails to efficiently cleave and interfere with mMAVS function. In turn, inefficient HCV interference with mMAVS in mouse cells may explain why HCV is unable to efficiently replicate in mouse cells with active innate immune signaling.
To test these hypotheses, we compared HCV interference with hMAVS and mMAVS. First, we stably expressed either human or mouse MAVS in MLT-MAVS Ϫ/Ϫ miR122 cells (Fig. 2) , followed by transient expression of the NS3-4A protease via lentiviral gene transduction. This method was chosen to mimic the expression of the protease in viral invasion independent of constraints on HCV RNA replication (e.g., due to lack of HCV replication-assisting cofactors). Both hMAVS ( Fig. 2A) and mMAVS (Fig. 2B) were partially cleaved upon transient coexpression of NS3-4A in MLT-MAVS Ϫ/Ϫ miR122 cells. This is either due to incomplete transduction of the cell populations with the HCV protease or due to incomplete cleavage of overexpressed MAVS proteins under these experimental conditions. Cleavage was specifically mediated by the viral protease, since coexpression of GFP did not induce cleavage and as addition of a protease inhibitor reduced cleavage of both hMAVS and mMAVS ( Fig. 2A and B) . When these cells were transfected with poly(I·C), coexpression of the HCV NS3-4A protease clearly lowered both hMAVS-and mMAVS-dependent production of IFN-␤ ( Fig. 2C and D) . Since the extents to which IFN-␤ production was suppressed were comparable between NS3-4A coexpressed with hMAVS and mMAVS, we conclude that in this system the HCV protease interferes with the function of these two MAVS proteins to similar levels. To exclude that species-specific signaling activity of hMAVS in mouse cells may mask differential HCV interference, we conducted principally similar cotransfection experiments with human HEK 293T cells, which upon transcription activator-like effector nuclease (TALEN)-mediated knockout of hMAVS lack endogenous expression of the adaptor protein (Fig. 3A) . Like in the mouse cells, we noted HCV NS3-4A-dependent cleavage of both MAVS species (Fig. 3A and B) . The appearance of partial cleavage of MAVS was mainly caused by the cotransfection efficiency issue, as not all cells were equally transfected with equal amounts and ratios of plasmids. Finally, using an IFN-␤ promoter-dependent luciferase reporter plasmid, we observed 5-to 10-fold-greater suppression of poly(I·C)-dependent IFN-␤ promoter activity by expression of the NS3-4A protease in the case of mMAVS than with hMAVS ( Fig. 3C and D) . Collectively, these results indicate that the HCV NS3-4A protease cleaves and interferes with the function of both mMAVS and hMAVS in human and mouse cells. Moreover, interference with the murine MAVS ortholog was not inferior to that with the human MAVS protein.
To investigate whether NS3-4A expressed from an autonomously replicating HCV RNA is sufficient to overcome restriction by hMAVS or mMAVS in MLT-MAVS Ϫ/Ϫ miR122 cells, we transfected a subgenomic HCV luciferase replicon into parental MLT-MAVS Ϫ/Ϫ miR122 cells or derivative cell lines stably expressing these MAVS variants. Irrespective of whether hMAVS or mMAVS was present, luciferase activity did not rise over the background level defined by the replication-inactive replicon mutant (Fig. 4A) . In parallel, only very inefficient cleavage of both MAVS variants was observed (Fig. 4B) , which likely results from initial production of viral protease translated from the input of transfected viral RNA. Taken together, these results indicate that HCV replication was suppressed to background levels in cells overexpressing either hMAVS or mMAVS.
Considering that overexpression of MAVS may preactivate cellular innate immune responses prior to transfection, thus ablating HCV replication, we chose an alternative experimental setting: MAVS proteins were introduced into MLT-MAVS Ϫ/Ϫ miR122 cells engineered to express a replicating HCV luciferase replicon (Fig. 4C) . In these experiments, the degree of MAVS overexpression was modulated by serially diluting the lentiviral stocks used for transduction of MAVS proteins (Fig. 4D) . Interestingly, both mMAVS and hMAVS restricted HCV replication in a dose-dependent fashion (Fig.  4E) , as evidenced by ca. 85% reduction of luciferase activity at the highest dose of MAVS expression compared with the overexpression of GFP. Notably, the two MAVS proteins were overexpressed to similar levels, as was evident from our protein expression analysis utilizing FLAG-specific antibodies to detect the FLAG-tagged hMAVS and mMAVS proteins transfected in these experiments (Fig. 4D) . Congruently, transfection of wildtype, untagged hMAVS and mMAVS proteins resulted in comparable and dose-dependent repression of HCV replication in MLT-MAVS Ϫ/Ϫ miR122 replicon cells (data not shown). Finally, FLAG-tagged hMAVS and mMAVS variants that are resistant to cleavage by the HCV NS3-4A protease due to mutation of the cleavage site exerted a further increased repression on HCV replication compared to that with the parental MAVS
FIG 2 Comparison HCV NS3-4A-dependent cleavage of and interference with hMAVS and mMAVS in mouse cells. (A and B) Human (A) or mouse (B) MAVS was expressed in MLT-MAVS
Ϫ/Ϫ miR122 cells in the presence or absence of GFP or the HCV NS3-4A protease. Expression of proteins was monitored by Western blotting using GFP-, actin-, mMAVS-, or hMAVS-specific antibodies. One day after lentiviral gene transduction, the medium was changed and the indicated cells were treated with addition of 10 M boceprevir, a protease inhibitor (P.I). Twenty-four hours later, the cells were lysed for specific Western blot analysis. The cleaved (⌬) products of hMAVS and mMAVS are indicated, and ␤-actin expression was used as a loading control. Images are representative of two individual experiments. (C and D) Effect of HCV NS3-4A protease expression on human (C) or mouse (D) MAVS-dependent type I IFN induction. One day after the cells were transduced, the cells were either mock transfected or transfected with 10 g/ml of poly(I·C). Four hours later, total RNA was extracted and the relative levels of mIFN-␤ mRNA expression were determined by qRT-PCR. Data were normalized to the mGAPDH mRNA data. Asterisks show a significant difference between the indicated data. Mean values Ϯ SDs from three independent experiments are given.
proteins that are susceptible to cleavage by HCV (ca. 3-fold) (Fig. 4E) . These results indicate that the ability of HCV to cleave MAVS facilitates HCV replication. Furthermore, since the degrees of restriction exerted by parental MAVS and the cleavage-resistant MAVS variant were in each case indistinguishable between the human and the mouse orthologs, we conclude that HCV is capable of interfering with mouse MAVS to a level similar to that of the human variant. As a consequence, it is unlikely that inefficient viral cleavage of mouse MAVS is the critical limitation that prevents HCV from propagating in mouse liver cells with intact innate immune signaling.
HCV replication in mouse liver tumor cells elicits production of both type I and III IFNs in a MAVS-dependent fashion.
Next, we dissected the mMAVS-regulated downstream signaling events responsible for limiting HCV replication in mouse cells. To this end, we first explored which type of IFN is produced upon administration of poly(I·C) or after transfection of HCV RNA. Using mIFN-␤ (type I IFN)-specific and mIFN-(type III IFN)-specific mRNA detection systems, we observed that both types of IFNs were vigorously upregulated upon extracellular addition or transfection of poly(I·C) to primary mouse hepatocytes (Fig. 5A ). In the case of MLT-MAVS Ϫ/Ϫ miR122 cells, repair of mMAVS expression led to rapid and strong induction of mIFN-␤ and mIFN-mRNA upon transfection of poly(I·C) (Fig. 5B) . Likewise, transfection of HCV replicon RNA also induced both types of IFNs (Fig. 5B) , indicating that HCV replication in MLT-MAVS Ϫ/Ϫ miR122 elicits type I and III IFN production in a mMAVS-dependent fashion. Both type I and III IFNs control HCV replication in mouse liver tumor cells. To assess if both types of IFN contribute to control of HCV replication in these cells, we first investigated if both primary mouse hepatocytes and MLT-MAVS Ϫ/Ϫ miR122 cells are responsive to these IFNs. To this end, we incubated these cells with exogenously added mouse IFN-␣ or mouse IFN-3 and monitored upregulation of the mRNAs of typical interferon-stimulated genes (ISGs). All three ISGs tested by us were clearly induced upon administration of either mIFN-␣ or mIFN-, indicating that these cells are responsive to both type I and III IFNs (Fig. 5C) . To explore the relevance of both types of IFNs for control of HCV replication in mouse liver-derived cells, we established a novel MLT cell line lacking both type I and III IFN receptors (MLT-IFNAR Ϫ/Ϫ IFNLR1 Ϫ/Ϫ miR122) (Fig. 6A ). When transfected with an HCV luciferase replicon, these cells sustained vigorous HCV RNA replication similar to that with MLT-MAVS Ϫ/Ϫ miR122 cells and somewhat greater than with MLT cells lacking endogenous expression of the type I IFN receptor 
alone (MLT-IFNAR
Ϫ/Ϫ miR122 [9] ) (Fig. 6B ). This observation was also corroborated by analysis of NS5A expression in the transfected cells showing larger numbers of NS5A-positive cells in the case of MAVS knockout and IFNAR plus IFNLR1 double knockout than with the IFNAR knockout alone (Fig. 6C) . Therefore, inactivation of MAVS or both type I and III IFN receptors together renders MLT cells highly permissive to HCV RNA replication. To confirm that the latter cells lack functional type I and III IFN receptors, we treated them with exogenous mIFN-␣ or different doses of mIFN-3 and used the nucleoside polymerase inhibitor 2=C-methyladenosine (2=CMA) as a control. As expected, the polymerase inhibitor reduced HCV replication in all three abovementioned cell lines (Fig. 6D) (Fig. 6D) . Finally, we repaired expression of IFNLR1 in the MLT cells with double knockout of type I and III IFN receptors using lentiviral gene transfer and monitored HCV replication in the presence or absence of mIFN-3 (Fig. 6E) . Reintroduction of the type III IFN receptor chain reduced HCV replication ca. 3-fold. Moreover, it also restored responsiveness of these cells to mIFN-3, as addition of this type of IFN further repressed HCV replication to a level ca. 10-fold lower than in mIFN-3-treated cells in the absence of IFNLR1 expression (Fig. 6E) . Collectively, these observations indicate that HCV replication in MLT cells is susceptible to suppression by both exogenous type I and III IFNs. Finally, we explored if MAVS-dependent upregulation of endogenous type I and III IFNs limits HCV replication in the MLT culture system by using the experimental setup detailed in Fig. 7A . To this end, we transduced mMAVS into MLT-MAVS
Ϫ/Ϫ miR122 cells that had been transfected with an HCV replicon. Subsequently, we monitored MAVS cleavage by HCV (Fig. 7B ) and the influence of mMAVS overexpression on HCV replication by using luciferase assays (Fig. 7C) . As expected, lentiviral gene transfer resulted in dose-dependent expression of mMAVS in all transduced cell lines and HCV NS3-4A partially cleaved overexpressed or endogenous mMAVS (Fig. 7B) . Reintroduction of mMAVS into MLT-MAVS Ϫ/Ϫ miR122 cells, which endogenously express both functional type I and III IFN receptors (Fig. 6) , suppressed HCV-dependent luciferase activity in a dosedependent fashion down to less than 10% at the highest dose of mMAVS expression (Fig. 7C) . Notably, mMAVS overexpression also suppressed HCV replication in MLT cells lacking the type I IFN receptor, albeit with modestly reduced efficacy (Fig. 7C) . In contrast, in cells that lack both type I and III IFN receptors, overexpression of mMAVS no longer was antiviral, as evidenced by stable high-level luciferase expression irrespective of the level of overexpressed mMAVS (Fig. 7C) . To examine if the antiviral activity was caused by mMAVS-dependent secretion of both type I and III IFNs, we assessed the bioactivity of the supernatants collected from the mMAVS-overexpressing MLT-IFNAR
Ϫ/Ϫ miR122 cells. To this end, these supernatants were filtered and passed onto MLT-MAVS Ϫ/Ϫ miR122, MLT-IFNAR Ϫ/Ϫ miR122, or MLT-IFNAR Ϫ/Ϫ IFNLR1 Ϫ/Ϫ miR122 cells that had been transfected with an HCV replicon (Fig. 7D) . The conditioned supernatants could suppress de novo HCV-dependent luciferase activity only in the MLT-MAVS Ϫ/Ϫ miR122 and MLT-IFNAR Ϫ/Ϫ miR122 cells and not in the MLT cells lacking both IFN receptors (Fig. 7D) , confirming the secretion of bioactive type I and III IFNs. Taken together, these data indicate that HCV replication in mouse-derived liver cells triggers mMAVS-dependent signaling which upregulates both type I and III IFNs, which, in turn, suppress HCV replication.
DISCUSSION
In this study, we showed that mMAVS-dependent innate immune signaling potently restricts HCV replication in mouse liver cells by way of inducing both type I and III IFN production. These results refine and extend previous in vitro and in vivo studies highlighting the fact that ablation of host proteins involved in innate immune signaling facilitates HCV replication in mouse cells (7) (8) (9) (10) . Notably, mMAVS does potently restrict HCV replication in mouse cells in spite of its susceptibility to cleavage by the CV NS3-4A protease, which was reported recently (31, 32) . However, it remained undetermined if the efficiency of cleavage paralleled that of hMAVS and if expression of mMAVS poses a greater degree of restriction on HCV replication than its human ortholog.
Therefore, we quantitatively and qualitatively compared the cleavage efficiencies of hMAVS and mMAVS by the HCV NS3-4A protease both in human and in mouse cells. Moreover, we explored to what level HCV interferes with the signaling activities of both proteins and how efficiently these two orthologs restrict HCV replication in mouse liver cells. Overexpressed HCV NS3-4A similarly diminished hMAVS-and mMAVS-dependent signaling in mouse (Fig. 2) and human (Fig. 3) cells. Moreover, replicon-encoded protease cleaved similar fractions of overexpressed hMAVS and mMAVS, as was evident from detection of these proteins via a FLAG tag (Fig. 4) . Therefore, although speciesspecific functioning of hMAVS and mMAVS in human and mouse cells cannot be fully ruled out, these analyses strongly suggest that in the human and mouse cells tested by us, cleavage and viral interference with hMAVS and mMAVS were comparable.
These novel findings have implications relevant to the development of immunocompetent mouse models for HCV. First, it is unlikely that inefficient mMAVS cleavage by HCV per se prevents efficient HCV replication in mouse liver cells. Therefore, MAVS function apparently does not pose an insurmountable barrier to HCV replication. Of note, in human cells, HCV NS3-4A also cleaves human TRIF, which transmits Toll-like receptor 3 (TLR-3)-dependent signaling for production of IFN (11) . Since there is controversy about whether mouse TRIF is susceptible to cleavage by HCV (32, 33) , it is possible that poor adaptation of HCV to interfere with TRIF-dependent signaling prevents efficient HCV replication in mouse cells. While resolving this question merits further work, it is also possible that lack of human replication cofactors limits replication and accumulation of HCV proteins to establish sufficient interference with innate immunity. If these cofactors were known, their ectopic expression in the mouse environment may reinforce HCV replication so that artificial ablation of MAVS-dependent (and/or TRIF-dependent) innate immunity is not necessary. The cell lines described in this study should be a useful platform to screen for such human replication cofactors, for instance, by cDNA library-based approaches.
An alternative approach to establish (pseudo)immunocompetent mouse models for HCV may be to selectively eliminate distinct IFN-expressed antiviral effector proteins to circumvent global elimination of central innate immunity signaling molecules. This study indicates that in the context of MLT cells, both type I-and III-dependent antiviral effector mechanisms are triggered by HCV replication which cooperate to efficiently suppress HCV replication. This conclusion is based on our observations that HCV RNA triggers both mouse IFN-␤ and IFN-mRNA expression (Fig. 5) and that HCV replication in MLT cells can be suppressed by exogenous administration of both type I and III IFNs (Fig. 6) . Moreover, we observed that MAVS signaling-dependent suppression of HCV replication mediated by secreted type I and type III IFNs was most pronounced in cells expressing both type I and III receptors, was reduced when the type I IFN receptor was lacking, and was fully ablated when both IFN receptors were absent (Fig. 7) . Although MAVS also directly activates interferon-stimulated genes (reference 34 and data not shown), 
IFNLR1
Ϫ/Ϫ miR122 cells with replicating HCV-SGR were collected, filtered with a 0.45-mm filter, and then used to treat de novo HCV-SGR replication in the indicated cells. Forty-eight hours later, the HCV RNA replication was measured by luciferase assays. Data are expressed relative to those for the mock-treated controls, and asterisks indicate a significant difference compared to each related mock group. All graph data are shown as mean values Ϯ SDs from three independent experiments, and Western blotting images are representative of two individual experiments.
this is apparently not sufficient to efficiently restrict HCV replication in the MLT cells lacking both IFN receptors (Fig. 7) . These data indicate that to mount a strong antiviral effect, it is necessary for MAVS-dependent antiviral effector mechanisms to involve signaling through type I and III IFN receptors. Further work will be needed to find out which IFN-dependent mouse effector proteins curtail HCV propagation. Evaluation of the type I-and III IFN-dependent gene expression signatures should provide interesting clues in this direction.
To what extent both type I and III IFNs limit HCV replication in mouse livers in vivo remains to be shown. Notably, a recent study concluded that type III IFN did not impact acute infection of mouse livers by hepatotropic viruses due to the absence of expression of the type III IFN receptor (35) . Given that expression of this receptor is tightly controlled by epigenetic mechanisms, it is possible that this may change in the course of a long-term (36), chronic infection. In any case, firm evidence derived from human liver cells and from chimpanzees firmly establishes that HCV induces both type I and III IFN responses which contribute to control of replication (13, 14, 16) . In this regard, the novel MLT cells described here may be useful not only to delineate species-specific restrictions for HCV replication in mouse liver cells but also to model both type I and III IFN-dependent HCV control mechanisms.
